X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Torrent Pharma Quarterly Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Torrent Pharma Quarterly Results   (TORR)

Here are the latest quarterly results of Torrent Pharma. For more details, see the Torrent Pharma financial fact sheet and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Torrent Pharma Quarterly Results

No. of Mths
Qtr. Ending
3
Dec-15
*
3
Mar-16
*
3
Jun-16
*
3
Sep-16
*
3
Dec-16
*
3
Mar-17
*
3
Jun-17
*
3
Sep-17
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m15,39014,99015,45014,29014,43014,34013,74014,290 
Other income Rs m5102402604305001,0401,050780 
Turnover Rs m15,90015,23015,71014,72014,93015,38014,79015,070 
Expenses Rs m9,26010,15011,08010,99011,27011,39010,77011,000 
Gross profit Rs m6,1304,8404,3703,3003,1602,9502,9703,290 
Depreciation Rs m610650680690730970800840 
Interest Rs m420380490510480580560510 
Profit before tax Rs m5,6104,0503,4602,5302,4502,4402,6602,720 
Tax Rs m780480540460160380780680 
Profit after tax Rs m4,8303,5702,9202,0702,2902,0601,8802,040 
Gross profit margin %39.832.328.323.121.920.621.623.0 
Effective tax rate %13.911.915.618.26.515.629.325.0 
Net profit margin %31.423.818.914.515.914.413.714.3 
Diluted EPS Rs 28.5 21.1 17.3 12.2 13.5 12.2 11.1 12.1  
Diluted EPS (TTM) Rs 93.2 106.6 97.3 79.1 64.1 55.2 49.0 48.9  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

More Pharmaceuticals Company Quarterly Results:   STRIDES SHASUN LTD  PIRAMAL ENTERPRISES  INDRAPRASTHA MEDICAL  UNICHEM LAB  PANACEA BIOTECH  

Compare TORRENT PHARMA With:   STRIDES SHASUN LTD  PIRAMAL ENTERPRISES  INDRAPRASTHA MEDICAL  UNICHEM LAB  PANACEA BIOTECH  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS